Reaching out for the next stage of Detoxification

3 in one Organ Support

Dieses Projekt wird/wurde kofinanziert von der Europäischen Union aus dem Europäischen Fonds für regionale Entwicklung.

Research & Development

In 2019 ProMedTec started a new R&D-project to develop an innovative dialysate for the effective CO2-removal under specific blood stream conditions.

This feasibility study is focusing on the idea to perform extracorporeal oxygenation combined with kidney and liver support using just one dialyzer. The device will integrate all active components, using just one enhanced blood flow circuit, reducing the needed volume, heat loss and minimizing the surface contact on the blood side to achieve a sustainable reduction of numerous potential side effects.

The project is realized in cooperation with the University of Rostock and has been supported by the TBI (Technologie-Beratungs-Institut GmbH) to receive funding from the European Union (EFRE).

Our Mission

Fighting multi organ failure!

In the first run, Promedtec aims to improve the overall outcomes for patients in multi organ failure by providing one advanced dialysis set-up to detoxify 3 organs at the same time.

The idea

What’s new

Multiple organ dysfunction is still a common cause of morbidity and mortality in intensive care units and while several clinical trials have demonstrated the high levels of mortality in patients with Multiple Organ Dysfunction Syndrome (MODS), currently available treatments have only experienced incremental innovation and gradual improvements over the past decade.

Our first priority

Rethinking the potential of extracorporeal support in critical care!

Our first priority – The essential needs of patients in intensive care units! Keeping an eye on both safety and usability, our innovative setup has just one goal: Maximizing the outcome of multiorgan support - detoxification & gas exchange! Minimize side effects, negative interactions & unwanted adverse effects

Offering a less complex, user-friendly & reliable device with clear performance parameters!

Creating a fundamentally new solution to treat patients with Multiple Organ Dysfunction Syndrome in intensive care, enabling physicians to spend more time on the patient instead of priming the device.

R&D-Status

Knowing that we address a more complex challenge in critical care our dedication to improve the conditions of patients in multi organ failure is the daily motivation to create a simple, flexible and reliable treatment kit – easy to use in combination with the traditional dialysis platforms receiving best in class results.

As we successfully applied for a grant in 2019, we could refine the first concept and showed positive results in a feasibility study in 2020 facing the seed phase in 2021 to reach the next level.

Meanwhile the technology is protected by patents and based on promising in-vitro data the team is now working on a sophisticated and scalable version of the prototype.

Taking advantage of

Extremely biocompatible filter technologies

While most of the currently available devices in dialysis have only experienced incremental innovation and gradual improvements this system is designed to support and replace 3 organs at the same time – Liver, Lung & Kidney – using one dialyzer to significantly reduce the complexity in the extracorporeal set-up.

Innovative blood flow solutions

The device integrates all active components, using just one enhanced blood flow circuit, reducing the needed volume, heat loss and minimizing the surface contact on the blood side to achieve a sustainable reduction of numerous potential side effects.

Disruptive oxygenation technology

Based on many years of experience in the research of flow dynamics we discovered an alternative way to the classical oxygenator in the blood stream to perform extracorporeal oxygenation. This new setup combined with kidney and liver support is a markable breakthrough in the treatment of multi organ failure as it will significantly optimize the risk benefit ratio using just one dialyzer to minimize the stress for the blood cells.

Enhanced dialysate components

The classical dialysate used in albumin-dialysis will be processed and enriched with several substances not only to increase the detoxification levels but to enable an efficient gas exchange in parallel.

Rethinking the treatment of Multi organ failure results in a completely new understanding of extracorporeal settings as a game-changing opportunity supporting patients in a very gentle but at the same time really effective way.

Company

Everything starts with the patient. We started helping patients to have access to selected treatments and surgeries. Building an excellent network in several niche markets we attracted industries attention and got involved in research and development for different extracorporeal organ support systems. Inspired by Dr. Stange’s second invention after Mars, which is still the global number one in liver support we used his new idea of Albumin dialysis as a blue print to develop our new understanding of multiorgan-support.

Based on our network this team is the perfect combination of industry veterans and practicing physicians with decades of subject-specific knowledge in organ support. Completed with talented and experienced scientists we are dedicated to one mission:

3inOne – Addressing detoxification & support of 3 organs with just one dialyzer!

The core team of ProMedTec

Dipl.-Kfm. Jan Klaiber

Prof. Dr. rer. nat. habil. Martin Eggert

Priv. Doz. Dr. med. habil. Jan Stange

Adrian Dominik, MSc

Investors

Become an investor

Join us today, fighting multi organ failure and help us to safe lives!

Because our device will have the potential to a paradigm shift treating these critical care patients!

Imagine simplifying the treatment of millions of patients in critical care suffering from multi organ failure with just one dialyzer in an extracorporeal setup – minimizing all the potential of side effects using different devices at the same time – maximizing the outcome with best in class results!

Multiple organ dysfunction is still a common cause of morbidity and mortality in intensive care units and while several clinical trials have demonstrated the high levels of mortality in patients with Multiple Organ Dysfunction Syndrome (MODS), currently available treatments have only experienced incremental innovation and gradual improvements over the past decade.

Contact

Office Rostock

Schillingallee 68
18057 Rostock
+49 (0) 381 494 7330

Office Bad Doberan

Goethestraße 2
18209 Bad Doberan
+49 (0) 38203 739298

Please contact us

Contact Form